<DOC>
	<DOC>NCT01072448</DOC>
	<brief_summary>This 12-week study evaluated the efficacy and safety of indacaterol versus placebo.</brief_summary>
	<brief_title>12-week Efficacy of Indacaterol</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<criteria>Inclusion criteria: Diagnosis of chronic obstructive pulmonary disease (COPD) (moderatetosevere as classified by the Global Initiative for Chronic Obstructive Lung Disease [GOLD] Guidelines, 2008) and: Smoking history of at least 10 packyears Postbronchodilator forced expiratory volume in 1 second (FEV1) &lt; 80% and â‰¥ 30% of the predicted normal value Postbronchodilator FEV1/FVC (forced vital capacity) &lt; 70% Exclusion criteria: Patients who have had a COPD exacerbation requiring systemic corticosteroids and/or antibiotics and/or hospitalization in the 6 weeks prior to screening Patients who have had a respiratory tract infection within 6 weeks prior to screening Patients with concomitant pulmonary disease Patients with a history of asthma Patients with diabetes Type I or uncontrolled diabetes Type II Any patient with lung cancer or a history of lung cancer Patients with a history of certain cardiovascular comorbid conditions Other protocoldefined inclusion/exclusion criteria applied to the study.</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>COPD</keyword>
	<keyword>indacaterol</keyword>
</DOC>